Isabel M. Jiménez-Sánchez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Isabel M. Jiménez-Sánchez has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Imane Allali-Bouamara
Allergy Research Group, IBIMA-Plataforma BIONAND, Instituto de Investigación Biomédica de Málaga, 29009 Malaga, Spain
2 shared publications - Inmaculada Doña
Allergy Research Group, IBIMA-Plataforma BIONAND, Instituto de Investigación Biomédica de Málaga, 29009 Malaga, Spain
2 shared publications - Jose Antonio Cornejo-Garcia
Allergy Research Group, IBIMA-Plataforma BIONAND, Instituto de Investigación Biomédica de Málaga, 29009 Malaga, Spain
2 shared publications - José Julio Laguna
Allergy Unit, Allergo‐Anesthesia Unit University Hospital of Cruz Roja and Faculty of Medicine and Biomedicine, Alfonso X El Sabio University Madrid Spain
2 shared publications - José Triano-Cornejo
Allergy Research Group, IBIMA-Plataforma BIONAND, Instituto de Investigación Biomédica de Málaga, 29009 Malaga, Spain
2 shared publications - Maria Jose Torres
Allergy Research Group, IBIMA-Plataforma BIONAND, Instituto de Investigación Biomédica de Málaga, 29009 Malaga, Spain
2 shared publications
Latest Publications
- Open Access
- 9 June 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (6) , 911
Correction: Jiménez-Sánchez et al. Antioxidant Enzymes Genetic Variants Associated with Urticaria/Angioedema Induced by Cross-Reactive Hypersensitivity to Nonsteroidal Anti-Inflammatory Drugs. Pharmaceuticals 2026, 19, 522
- 9 June 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (6) , 911
Open AccessCorrection: Jiménez-Sánchez et al. Antioxidant Enzymes Genetic Variants Associated with Urticaria/Angioedema Induced by Cross-Reactive Hypersensitivity to Nonsteroidal Anti-Inflammatory Drugs. Pharmaceuticals 2026, 19, 522
- Open Access
- 24 March 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (4) , 522
Antioxidant Enzymes Genetic Variants Associated with Urticaria/Angioedema Induced by Cross-Reactive Hypersensitivity to Nonsteroidal Anti-Inflammatory Drugs
Background/Objectives: Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most consumed drugs worldwide and the main cause of drug hypersensitivity reactions (HSRs). The most common NSAID-HSR class is cross-hypersensitivity (CR), with patients reacting to NSAIDs from different chemical groups without specific immunological recognition, with NSAID-induced acute urticaria/angioedema (NIUA) being the most frequent clinical phenotype. Although CR-HSRs are triggered by arachidonic acid (AA) alterations following cyclooxygenase (COX)-1 inhibition and cysteinyl-leukotrienes synthesis by 5-lypoxygenase (5-LO), current evidence supports the participation of additional mechanisms. As COX-1 and 5-LO head oxidative pathways, it is conceivable that enzymes participating in antioxidant control are involved in these mechanisms. In addition, as the CR-HSR susceptibility seems to be influenced by genetic factors, the possibility of genetic variants playing a role in such enzymes should not be excluded. Methods: In this observational case–control study, we analysed for the first time in NIUA the overall genetic variability in key antioxidant defence enzymes genes, including catalase (CAT), glutathione peroxidase (GPX)-1 and 3, and superoxide dismutase (SOD)-1. We selected a set of tagging single nucleotide polymorphisms (tSNPs) in these genes using data from Europeans in the 1000 Genomes Project. Two independent Spanish populations (discovery and replication) of NIUA patients and NSAID-tolerant individuals were included. Results: Twenty-six tSNPs were genotyped in the discovery population, with three that were significantly associated with NIUA: rs3448 (GPX-1), rs3792798 (GPX-3), and rs10432782 (SOD-1). They were then genotyped in the replication group, with rs3792798 being protective and rs10432782 being associated with an increased NIUA risk. Conclusions: Our results suggest that a role for antioxidant enzyme polymorphisms in NIUA is required. Nevertheless, further research is needed to replicate our findings in other populations and their meaning at the molecular level and to investigate the role of such variants in other CR-HSR-induced phenotypes.
- 24 March 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (4) , 522
Open AccessAntioxidant Enzymes Genetic Variants Associated with Urticaria/Angioedema Induced by Cross-Reactive Hypersensitivity to Nonsteroidal Anti-Inflammatory Drugs
Background/Objectives: Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most consumed drugs worldwide and the main cause of drug hypersensitivity reactions (HSRs). The most common NSAID-HSR class is cross-hypersensitivity (CR), with patients reacting to NSAIDs from different chemical groups without specific immunological recognition, with NSAID-induced acute urticaria/angioedema (NIUA) being the most frequent clinical phenotype. Although CR-HSRs are triggered by arachidonic acid (AA) alterations following cyclooxygenase (COX)-1 inhibition and cysteinyl-leukotrienes synthesis by 5-lypoxygenase (5-LO), current evidence supports the participation of additional mechanisms. As COX-1 and 5-LO head oxidative pathways, it is conceivable that enzymes participating in antioxidant control are involved in these mechanisms. In addition, as the CR-HSR susceptibility seems to be influenced by genetic factors, the possibility of genetic variants playing a role in such enzymes should not be excluded. Methods: In this observational case–control study, we analysed for the first time in NIUA the overall genetic variability in key antioxidant defence enzymes genes, including catalase (CAT), glutathione peroxidase (GPX)-1 and 3, and superoxide dismutase (SOD)-1. We selected a set of tagging single nucleotide polymorphisms (tSNPs) in these genes using data from Europeans in the 1000 Genomes Project. Two independent Spanish populations (discovery and replication) of NIUA patients and NSAID-tolerant individuals were included. Results: Twenty-six tSNPs were genotyped in the discovery population, with three that were significantly associated with NIUA: rs3448 (GPX-1), rs3792798 (GPX-3), and rs10432782 (SOD-1). They were then genotyped in the replication group, with rs3792798 being protective and rs10432782 being associated with an increased NIUA risk. Conclusions: Our results suggest that a role for antioxidant enzyme polymorphisms in NIUA is required. Nevertheless, further research is needed to replicate our findings in other populations and their meaning at the molecular level and to investigate the role of such variants in other CR-HSR-induced phenotypes.